Did Mesoblast beat or miss consensus estimates last quarter?

What guidance did Mesoblast's management provide for the next earnings period?

What were the key takeaways from Mesoblast’s earnings call?

What is the market's earnings forecast for Mesoblast next quarter?

What is Mesoblast's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Mesoblast year over year?

What were the key takeaways from Mesoblast's earnings call?

What factors drove the changes in Mesoblast's revenue and profit?

- **Ryoncil Growth**: FY 2026 revenue guidance of $110-120 million, with 49 centers onboarded and 20% market share target by year-end.
- **Financial Strength**: $130 million cash on hand and $125 million credit facility to support growth.
- **Pipeline Momentum**: Rexlemestrocel-L Phase III enrollment complete; Revascor BLA filing for full approval in Q2 2026.
- **Strategic Expansion**: Adult GVHD trial underway, targeting a 3x larger market than pediatric GVHD.

**【CEO Summary Section】**
- Mesoblast highlighted its corporate priorities for 2026, focusing on Ryoncil sales growth, cash flow optimization, and label expansion into adult GVHD. The company aims to achieve a 20% market share in the pediatric GVHD market by year-end and is targeting a 40% peak share over time.
- Ryoncil net revenue reached $49 million in the first half of FY 2026, with 49 treatment centers onboarded and 30 formulary listings. The product is covered by insurance plans representing over 280 million lives.
- The company secured a $125 million nondilutive credit facility, with $75 million drawn to refinance prior debt, improving its financial flexibility.

**【CFO Financial Commentary】**
- Total first-half revenue was $51.3 million, driven by Ryoncil sales. Gross margin was 93%, with R&D expenses at $46.2 million and SG&A costs at $28.5 million.
- The company reported a net loss of $40.2 million, narrower than the prior year's $48 million loss (excluding a $23 million inventory provision reversal). Cash reserves stood at $130 million as of December 2025.
- Full-year 2026 Ryoncil revenue guidance is $110-120 million, with expectations for declining operating cash flow usage in the second half.

**【CCO Commercial Highlights】**
- Marcelo Santoro emphasized Ryoncil's rapid adoption, with 49 centers treating patients and 30 formulary listings secured within six months. The product is listed on 94% of pediatric bone marrow transplant centers.
- Strategic focus includes proactive patient identification, reinforcing first-line treatment outcomes, and empowering caregivers to advocate for Ryoncil.

**【Pipeline Updates】**
- Rexlemestrocel-L for chronic low back pain is enrolling a 300-patient Phase III trial, with BLA filing expected in 2027. The product has RMAT designation for opioid-sparing therapy.
- Revascor for end-stage heart failure with LVADs achieved a fivefold reduction in major bleeding events in a 159-patient trial. The company plans to file for full FDA approval in the next quarter.
- Ryoncil expansion into adult GVHD is progressing with a pivotal trial protocol locked and FDA alignment on design.

**【Q&A Highlights】**
- CFO reaffirmed full-year Ryoncil revenue guidance of $110-120 million, citing strong commercial momentum and disciplined cost management.
- CEO noted FDA confirmation that a 12-month pain reduction endpoint is approvable for rexlemestrocel-L in chronic back pain.
- Revascor BLA filing will include data from both ischemic and non-ischemic heart failure patients, with a focus on randomized controlled trial results.


Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript

- **Revenue Surge**: $17.2M in FY2025, 191% YoY growth, driven by Ryoncil's 90% gross margin.
- **Market Expansion**: $10B+ addressable markets for heart failure and low back pain; IBD trials to begin Q4 2025.
- **Clinical Success**: 70% response rate in pediatric GvHD; 76% 100-day survival in adult compassionate care program.
- **Trial Momentum**: 40 sites enrolling for low back pain trial; FDA alignment on heart failure accelerated approval.
- **Cost Efficiency**: Stable 14.6% gross-to-net adjustment; $162M cash runway for growth.

**【CEO Opening Remarks】**
- Launched Ryoncil, the first FDA-approved mesenchymal stromal cell (MSC) therapy, achieving $17.2 million in revenue (191% YoY growth) with 90% gross margin.
- Expanded access to 32 transplant centers, covering 250 million U.S. lives, with Medicaid coverage mandated nationwide.
- Addressable markets include $1 billion for pediatric GvHD, $5 billion for IBD, and $10 billion each for heart failure and chronic low back pain.

**【CFO Financial Commentary】**
- FY2025 revenue: $17.2 million (191% YoY), with $11.3 million net sales after 14.6% gross-to-net adjustment.
- Operating expenses: $39.3 million (14% YoY increase) due to commercial team expansion.
- Cash position: $162 million, supporting ongoing trials and commercial activities.

**【CEO Product Updates】**
- **Ryoncil**: 70% response rate in pediatric GvHD Phase III trial; compassionate care program shows 76% 100-day survival in adults.
- **Rexlemestrocel-L**: Phase III trials for heart failure and low back pain show 36-month pain reduction; FDA alignment on accelerated approval pathway.
- **IBD Expansion**: Planning pivotal trials for ulcerative colitis and Crohn's disease, targeting early remission in biologic-refractory patients.

**【Q&A Highlights】**
- **Sales Distribution**: Kits used predominantly for pediatric GvHD, with no visibility on off-label use.
- **Adult GvHD Trial**: Expected to commence Q4 2025, combining Ryoncil with ruxolitinib in severe Grade C/D patients.
- **Back Pain Trial**: 40 U.S. sites enrolling; 3x opioid cessation rate in prior trial.
- **Heart Failure**: Confirmatory trial design aligned with FDA; potential accelerated approval in 2026.
- **Gross-to-Net Stability**: 14.6% adjustment expected to remain consistent.


Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript

- **Breakthrough Pediatric GVHD Therapy**: RYONCIL approved for 375 U.S. children/year, priced at $194,000/infusion, with 70% response rate and 49% 4-year survival vs. 14% GVHD-related deaths.
- **Strong Financial Position**: $200M cash post-private placement, 22% YoY operating cash spend reduction, and key non-cash adjustments supporting H1 FY2025 loss of $47.9M.
- **Expansion Opportunities**: 60% of IBD patients refractory to biologics, 73% 100-day survival in adult GVHD pilot, and 50% pain remission in chronic back pain trial.
- **Accelerated Approval Pathway**: Heart failure program shows 80% cardiovascular death risk reduction, with FDA discussions for accelerated filing.
- **Commercial Execution**: 9-person sales team targeting 80% of U.S. transplant centers, with pre-launch engagement and inbound demand already strong.


**【CEO Opening Remarks】**
- Mesoblast is the global leader in allogeneic cellular medicines for inflammatory diseases, with RYONCIL as the first FDA-approved off-the-shelf therapy for pediatric steroid-refractory acute GVHD.
- RYONCIL's Phase 3 trial showed a 70% overall response rate at day 28, with 89% of patients having severe Grade C/D disease. Long-term survival rates at 4 years were 49%, significantly outperforming historical outcomes.
- The addressable market for pediatric GVHD in the U.S. is approximately 375 new patients annually, with a wholesale acquisition cost of $194,000 per infusion.

**【CFO Financial Highlights】**
- Cash balance as of December 31, 2024: $38 million (pre-private placement) / $200 million (post-private placement raising $161 million).
- Net operating cash spend for H1 FY2025: $20.7 million, a 22% reduction vs. H1 FY2024.
- Key non-cash adjustments: $23 million inventory provision reversal, $4 million contingent consideration remeasurement, and $16 million warrant liability remeasurement.
- Loss after tax for H1 FY2025: $47.9 million, driven by balance sheet adjustments.

**【CEO Product Updates】**
- **RYONCIL Launch Strategy**: Staged rollout targeting 45 highest-volume transplant centers (80% of U.S. market). Sales force of 9 key account managers already engaged with centers.
- **Inflammatory Bowel Disease Expansion**: Pilot data shows potential for RYONCIL in pediatric Crohn's disease and ulcerative colitis, with 60% of patients refractory to anti-TNF agents.
- **Adult GVHD Pipeline**: Pivotal trial planned for RYONCIL in ruxolitinib-refractory adults, with 73% 100-day survival in pilot study vs. 20%-30% historical rates.
- **Rexlemestrocel for Chronic Low Back Pain**: Phase III trial enrolling across 40 U.S. sites, with 50% of treated patients achieving pain remission at 12 months.
- **Heart Failure Program**: FDA discussions underway for accelerated approval of rexlemestrocel in ischemic heart failure, with DREAM trial showing 80% reduction in cardiovascular death risk.

**【Q&A Key Takeaways】**
- **Sales Force Execution**: 9-person sales team targeting 45 key centers, with pre-launch engagement already underway. Multiple inbound inquiries for immediate access.
- **Payer Feedback**: Positive discussions with payers, emphasizing the low patient volume (375/year) and RYONCIL's $3.2-$4.1 million lifetime value vs. $1.5 million treatment cost.
- **Back Pain Trial Momentum**: Enrollment ramping to 40 sites, with 20+ patients in screening. Potential data readout by end-2025, with U.S. partnership likely for commercialization.
- **Heart Failure Regulatory Pathway**: FDA open to accelerated approval based on DREAM trial data, with confirmatory trial design discussions pending.


Actual								-0.2693	-0.5689	-0.3992	-0.4153	-0.4162	-0.3034	-0.3309	-0.3793	-0.311	-0.3224	-0.2304	-0.3148	-0.2399	-0.2655							-0.311
Forecast								-0.3451	-0.3337	-0.0664	-0.2402	-0.0759	-0.1849	-0.365	-0.3856	-0.256	-0.1944	-0.3097	-0.2655	-0.3148	-0.2769							-0.237
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+21.96%	-70.48%	-501.20%	-72.90%	-448.35%	-64.09%	+9.34%	+1.63%	-21.48%	-65.84%	+25.61%	-18.57%	+23.79%	+4.12%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-31.22%

Actual	--	--	--	--	--	--	--	12.20M	701.00K	1.30M	2.24M	1.92M	2.00M	2.40M	2.38M	2.01M	2.21M	1.50M	2.13M	1.94M	1.90M	--	--	--	--	--	--	51.34M
Forecast	--	--	--	--	--	--	--	9.05M	12.71M	40.58M	15.63M	29.20M	17.71M	2.35M	3.50M	2.10M	7.59M	3.47M	2.10M	2.14M	2.38M	--	--	--	--	--	--	53.06M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+34.80%	-94.48%	-96.78%	-85.66%	-93.44%	-88.72%	+2.32%	-31.91%	-4.24%	-70.86%	-56.64%	+1.62%	-9.38%	-20.28%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3.25%

MESO

MESO fundamentals

MESO Q2 2026 Earnings

Earnings Call

You can ask Aime

MESO

MESO fundamentals

MESO Q2 2026 Earnings

Earnings Call

MESO Earnings Call Summary for Q2/20265:00 PM on Feb 26, 2026

MESO Earnings Call Summary for Q4/20256:30 PM on Aug 28, 2025

MESO Earnings Call Summary for Q3/2025 Mar 26, 2026

MESO Earnings Call Summary for Q2/20255:00 PM on Feb 26, 2025

MESO Earnings Call Summary for Q4/2024 Mar 26, 2026

You can ask Aime